← Back to Screener
CDT Equity Inc. Common Stock (CDT)
Price$3.35
Favorite Metrics
Price vs S&P 500 (26W)-105.22%
Price vs S&P 500 (4W)-81.06%
Market Capitalization$16.81M
All Metrics
Book Value / Share (Quarterly)$83.78
P/TBV (Annual)0.99x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-194.90
Price vs S&P 500 (YTD)-93.33%
EPS (TTM)$-5583.58
10-Day Avg Trading Volume0.15M
EPS Excl Extra (TTM)$-5583.58
EPS (Annual)$-1177.90
ROI (Annual)0.58%
Cash / Share (Quarterly)$16.38
ROA (Last FY)-694.23%
EBITD / Share (TTM)$-1182.28
Cash Flow / Share (Annual)$-194.90
P/B Ratio3.93x
P/B Ratio (Quarterly)0.49x
Net Income / Employee (Annual)$-7
Net Interest Coverage (TTM)-56.85x
ROA (TTM)-536.96%
EPS Incl Extra (Annual)$-1177.90
Current Ratio (Annual)0.34x
Quick Ratio (Quarterly)0.12x
3-Month Avg Trading Volume0.06M
52-Week Price Return-99.85%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.73
52-Week High$3030.00
EPS Excl Extra (Annual)$-1177.90
26-Week Price Return-96.47%
Quick Ratio (Annual)0.12x
13-Week Price Return-90.11%
Current Ratio (Quarterly)0.34x
Enterprise Value$15.961
Revenue / Employee (Annual)$0
Cash / Share (Annual)$16.38
3-Month Return Std Dev186.10%
Net Income / Employee (TTM)$-7
ROE (Last FY)0.60%
Net Interest Coverage (Annual)-135.14x
EPS Basic Excl Extra (Annual)$-1177.90
EV / Free Cash Flow (TTM)1093.68x
Total Debt / Equity (Quarterly)0.40x
EPS Incl Extra (TTM)$-5583.58
ROI (TTM)0.69%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.66
Price vs S&P 500 (52W)-134.95%
Year-to-Date Return-89.19%
5-Day Price Return-30.52%
EPS Normalized (Annual)$-1177.90
Month-to-Date Return-32.16%
Cash Flow / Share (TTM)$0.01
EBITD / Share (Annual)$-1156.91
EPS Basic Excl Extra (TTM)$-5583.58
P/TBV (Quarterly)7.69x
P/B Ratio (Annual)0.23x
Book Value / Share (Annual)$7.66
Price vs S&P 500 (13W)-92.98%
Beta1.87x
Revenue / Share (TTM)$0.00
ROE (TTM)0.68%
52-Week Low$2.60
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CDTCDT Equity Inc. Common Stock | — | — | — | — | $3.35 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
CDT Equity Inc. is a biopharmaceutical development company that uses artificial intelligence and advanced chemistry to identify and accelerate the development of novel therapeutic treatments. The company creates shareholder value by licensing assets, pursuing strategic acquisitions, and repositioning high-potential drug candidates to market faster. Operating as an agile platform-based model, CDT focuses on transformative innovation across its therapeutic portfolio.